-
Mashup Score: 1Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting | GU Oncology Now - 1 year(s) ago
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
GU Oncology Now
Genitourinary OncologyGU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and more, highlighting important advancements in genitourinary oncology treatments and technologies with the goal of better informing oncology decisions and improving patient outcomes.
-
Mashup Score: 9Sequential Endoluminal Chemotherapy for Non-Invasive High-Grade UTUC | GU Oncology Now - 1 year(s) ago
Drs. Packiam and Murray weigh multiple studies exploring gemcitabine/docetaxel as a frontline therapy for UTUC.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 @VigneshPackiam of @RutgersCancer, and @KSMurrayUro of @NYUUrology, weigh multiple recent studies that explore the efficacy of #gemcitabine/#docetaxel as a frontline therapy for #UTUC. 👉 Watch Now: https://t.co/6ernj0QNtC https://t.co/ryCQW14bmE
-
-
Mashup Score: 1Updated ENVISION Data: UGN-102 Shows 82.3% Duration of Response in LG-IR-NMIBC | GU Oncology Now - 1 year(s) ago
Dr. Prasad provides updates on the positive DOR data observed with UGN-102 for LG-IR-NMIBC in the ENVISION trial.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Watch our conversation with Sandip Prasad, MD, MPhil, on the positive duration of response data observed with #UGN102 for the treatment of LG-IR-#NMIBC in the #ENVISION trial. 👀 Watch Here: https://t.co/slxXrWx1tW https://t.co/2rx5gal4oN
-
-
Mashup Score: 4Safety Considerations for 89Zr-girentuximab PET/CT Imaging in ccRCC | GU Oncology Now - 1 year(s) ago
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🎥 Check out @DrRanaMcKay's thoughts on safety considerations for 89Zr-#girentuximab #PET/#CT imaging in #ccRCC. 👉 Watch the Full Video Here: https://t.co/J6ueEIsSbt https://t.co/HtS9AoTHxY
-
-
Mashup Score: 0
Read the full article here
Tweet-
Niklas Klümper, MD, of University Hospital Bonn, highlights an analysis of NECTIN4 amplification as a biomarker for predicting response to enfortumab vedotin in metastatic urothelial carcinoma treatment, with comments on its implications for clinical practice and ongoing research efforts.
-
🎥 Don't miss our conversation with Vishu Murthy of @dgsomucla, on the efficacy and toxicity of 177Lu-PSMA-617 for patients with #mCRPC. 📺 Watch Now: https://t.co/WBrpP3yxCO https://t.co/JEb34A5cXH